| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 10/04/2011 | CA2438520C Phthalazinone-piperidino-derivatives as pde4 inhibitors |
| 09/29/2011 | WO2011120040A2 Thrombin inhibiting compositions |
| 09/29/2011 | WO2011119939A2 Manipulation of calcium channels to regulate after-depolarization events in cardiac myocytes |
| 09/29/2011 | WO2011119919A1 Adenosine compounds and their use thereof |
| 09/29/2011 | WO2011119009A2 Peptides for promoting angiogenesis and an use thereof |
| 09/29/2011 | WO2011118928A2 Pharmaceutical composition for preventing or treating heart failure and method for screening agent for preventing or treating heart failure |
| 09/29/2011 | WO2011118795A1 Composition for treatment of damaged part |
| 09/29/2011 | WO2011117559A1 Proangiogenic compositions, method for preparing same, and uses thereof |
| 09/29/2011 | WO2011062766A3 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| 09/29/2011 | WO2011050379A9 Use of gstp1 |
| 09/29/2011 | WO2011050319A3 Inhibiting the deleterious effect of anthracyclines |
| 09/29/2011 | WO2010149760A3 Mexiletine amino acid and peptide prodrugs and uses thereof |
| 09/29/2011 | US20110238003 Method for systemic drug delivery through the nail |
| 09/29/2011 | US20110237783 Hydrazonopyrazole derivatives and their use as therapeutics |
| 09/29/2011 | US20110237672 Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production |
| 09/29/2011 | US20110237669 Polyunsaturated Fatty Acids Interactions and Oxidative Stress Disorders |
| 09/29/2011 | US20110237662 Use of Statins to Inhibit Inflammation and Vascular Disease |
| 09/29/2011 | US20110237659 Chromenone derivatives as trpv3 antagonists |
| 09/29/2011 | US20110237655 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use |
| 09/29/2011 | US20110237651 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
| 09/29/2011 | US20110237650 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| 09/29/2011 | US20110237649 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
| 09/29/2011 | US20110237648 Rna interference in skin indications |
| 09/29/2011 | US20110237645 USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3 |
| 09/29/2011 | US20110237635 Tetrahydronaphthalene derivatives |
| 09/29/2011 | US20110237634 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 |
| 09/29/2011 | US20110237633 Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 09/29/2011 | US20110237631 Selective Glycosidase Inhibitors and Uses Thereof |
| 09/29/2011 | US20110237630 Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
| 09/29/2011 | US20110237629 Amino acid ester prodrugs and the use thereof |
| 09/29/2011 | US20110237625 SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS |
| 09/29/2011 | US20110237622 Renin inhibitors |
| 09/29/2011 | US20110237617 Thieno[2,3-c] isoquinolines for use as inhibitors of parp |
| 09/29/2011 | US20110237613 Dha esters and use thereof in treatment and prevention of cardiovascular disease |
| 09/29/2011 | US20110237607 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| 09/29/2011 | US20110237604 Methods for preventing or treating cardiac arrhythmia |
| 09/29/2011 | US20110237603 Compositions of azimilide dihydrochloride |
| 09/29/2011 | US20110237601 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| 09/29/2011 | US20110237596 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| 09/29/2011 | US20110237592 Substituted amido phenoxybenzamides |
| 09/29/2011 | US20110237589 Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors |
| 09/29/2011 | US20110237586 Biaryl compositions and methods for modulating a kinase cascade |
| 09/29/2011 | US20110237583 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| 09/29/2011 | US20110237581 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 09/29/2011 | US20110237575 Inhibitors of fatty acid binding protein (fabp) |
| 09/29/2011 | US20110237574 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 09/29/2011 | US20110237559 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 |
| 09/29/2011 | US20110237546 Method for treating a mammal by administration of a compound having the ability to release co |
| 09/29/2011 | US20110237545 Trihydroxy polyunsaturated eicosanoid derivatives |
| 09/29/2011 | US20110237544 Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use |
| 09/29/2011 | US20110237541 Transdermally administered aliskiren |
| 09/29/2011 | US20110237538 Treatment of lysosomal storage disorders and other proteostatic diseases |
| 09/29/2011 | US20110237532 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
| 09/29/2011 | US20110237527 Sglt-2 inhibitors, methods of making them, and uses thereof |
| 09/29/2011 | US20110237526 Method for the preparation of a crystalline form |
| 09/29/2011 | US20110237511 EP4 Receptor Agonist, Compositions and Methods Thereof |
| 09/29/2011 | US20110237508 Peptide Formulations and Uses Thereof |
| 09/29/2011 | US20110237505 Compositions and Methods for Treating Obesity and Diabetes |
| 09/29/2011 | US20110237496 Antinecrotic activity of alpha 1-antitrypsin |
| 09/29/2011 | US20110237494 Use of peptidic vasopression receptor agonists |
| 09/29/2011 | US20110236508 L-arginine-based formulation for oral absorption |
| 09/29/2011 | US20110236488 Herbal formulation for prevention and treatment of diabetes and associated complications |
| 09/29/2011 | US20110236476 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| 09/29/2011 | US20110236473 Stable aliskiren formulations |
| 09/29/2011 | US20110236438 Method of treatment of diseases using hoodia extracts |
| 09/29/2011 | US20110236431 Treatment of acute myocardial infarction (ami) using encapsulated cells encoding and secreting glp-1 peptides or analogs thereof |
| 09/29/2011 | US20110236394 Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
| 09/29/2011 | US20110236389 Human Angiostatin Interacting and Tumor Metastasis Involving Protein Variants and Uses Thereof |
| 09/29/2011 | US20110236388 Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
| 09/29/2011 | US20110236386 Novel method for prediction of cardiovascular disease risk in type 2 diabetes |
| 09/29/2011 | US20110236365 Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage |
| 09/29/2011 | US20110236356 Methods of isolating and using stem cells |
| 09/29/2011 | US20110236352 PEGylation by the Dock and Lock (DNL) Technique |
| 09/29/2011 | US20110236340 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
| 09/29/2011 | US20110236317 Tetrahydrotriazine compounds for treating diseases associated with ampk acitivity |
| 09/29/2011 | US20110236312 Nucleoside analogues useful as positron emission tomography (pet) imaging agents |
| 09/29/2011 | US20110232650 Articles of clothing comprising ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors |
| 09/29/2011 | CA2793985A1 Proangiogenic compositions, method for preparing same, and uses thereof |
| 09/29/2011 | CA2792265A1 Adenosine compounds and their use thereof |
| 09/28/2011 | EP2368910A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 09/28/2011 | EP2368898A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 09/28/2011 | EP2368876A1 Derivatives of aminoindanes, their preparation and their application in therapeutics |
| 09/28/2011 | EP2368567A1 Non-neurotoxic plasminogen activating factors for treating strokes |
| 09/28/2011 | EP2368565A1 Enrichment of pre-beta high density lipoproteins |
| 09/28/2011 | EP2368559A2 Composition for preventing or treating artherosclerosis |
| 09/28/2011 | EP2367830A1 1-oxa-8-azaspiro [4, 5] decane- 8 -carboxamide compounds as faah inhibitors |
| 09/28/2011 | EP2367803A1 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases |
| 09/28/2011 | EP2367801A1 Polar quinazolines as liver x receptors ( lxrs ) modulators |
| 09/28/2011 | EP2367797A1 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| 09/28/2011 | EP2367791A1 Perindopril tosylate |
| 09/28/2011 | EP2367598A2 Inhibitors of diacylglycerol acyltransferase |
| 09/28/2011 | EP2367564A1 Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| 09/28/2011 | EP2367432A1 Infarct area perfusion-improving compositions and methods of vascular injury repair |
| 09/28/2011 | EP2133335B1 Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor |
| 09/28/2011 | EP1463531B1 Methods for inhibiting ocular processes |
| 09/28/2011 | EP1424330B1 Activator for peroxisome proliferator-responsive receptor delta |
| 09/28/2011 | EP1420800B1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity |
| 09/28/2011 | EP1414386B1 Canine cardiac diet |
| 09/28/2011 | EP1353684B8 Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia |
| 09/28/2011 | EP1237891B1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |